OncoMatch/Clinical Trials/NCT06934889
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Official title: Phase Ib Trial of ABBV-637 or ABBV-155 in Combination With ERAS-801 for Glioblastoma With Amplification of the Epidermal Growth Factor Receptor
Is NCT06934889 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies multiple treatments including ERAS-801 and ABBV-637 for glioblastoma.
Treatment: ERAS-801 · ABBV-637 · ABBV-155 · Temozolomide — The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Glioblastoma
Biomarker criteria
Required: EGFR amplification
Required: IDH1 wild-type
Disease stage
Required: Stage IV (other)
Grade: 4 (WHO)
WHO Grade IV Glioblastoma/Gliosarcoma using WHO 2021 criteria; measurable disease as per RANO criteria
Prior therapy
Cannot have received: EGFR-targeted therapy
Exception: eligible if surgery on recurrence after EGFR-targeted therapy confirmed persistence of an EGFR alteration
Patients with prior therapy with EGFR targeting agents are ineligible because treatment with EGFR kinase inhibitors or other EGFR-targeted agents has the potential to deplete the tumor of EGFR-amplified or EGFR mutant cell populations and confound the evaluation of the investigational regimen. Patients would only be eligible if surgery on a recurrence after the EGFR-targeted therapy confirmed persistence of an EGFR alteration.
Lab requirements
Blood counts
Absolute neutrophil count >1,200/mcL; Platelets >100,000/mcL; Hemoglobin > 9 g/dL
Kidney function
Creatinine ≤ institutional upper limit of normal OR Creatinine clearance >60 ml/min/1.73m2 for patients with creatinine levels above institutional normal
Liver function
Total bilirubin ≤ institutional upper limit of normal, or ≤ 3.0 mg/dL for subjects with Gilbert's syndrome; AST (SGOT) and ALT (SGPT) ≤ 3 × institutional upper limit of normal
Cardiac function
Echocardiogram with ejection fraction ≥ 50% and no other clinically significant finding; 12-lead ECG within 2 weeks of treatment start with QTc < 450 msec (using Fridericia's correction), and no clinically significant abnormalities
Patients must have the following organ and marrow function: 1. Absolute neutrophil count >1,200/mcL 2. Platelets >100,000/mcL 3. Hemoglobin > 9 g/dL . 4. Total bilirubin ≤ institutional upper limit of normal, or ≤ 3.0 mg/dL for subjects with Gilbert's syndrome 5. AST (SGOT) and ALT (SGPT) ≤ 3 × institutional upper limit of normal 6. Creatinine ≤ institutional upper limit of normal OR Creatinine clearance >60 ml/min/1.73m2 for patients with creatinine levels above institutional normal 7. APTT/PTT ≤ 1.5 x institutional upper limit of normal. Echocardiogram with ejection fraction ≥ 50% and no other clinically significant finding. 12-lead electrocardiogram ... with QTc < 450 msec (using Fridericia's correction), and no clinically significant abnormalities.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, Los Angeles (Data Collection Only) · Los Angeles, California
- University of Miami (Data collection only) · Miami, Florida
- Indiana University (Data Collection Only) · Indianapolis, Indiana
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06934889 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior EGFR-targeted therapy disqualifies patients from enrollment.
Does this trial require EGFR?
Yes, EGFR amplification is a required biomarker for enrollment.
Does this trial require IDH1?
Yes, IDH1 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages